Jaguar Animal Health Inc. (JAGX)
NASDAQ:JAGX
Want to see JAGX full AI Analyst Report?
JAGX Stock Chart & Stats
$1.28
-$0.07(-5.93%)
At close: 4:00 PM EST
$1.28
-$0.07(-5.93%)
Day’s Range― - ―
52-Week Range$0.24 - $13.25
Previous CloseN/A
Volume188.05K
Average Volume (3M)515.32K
Market Cap
$3.65M
Enterprise Value$43.20M
Total Cash (Recent Filing)$968.00K
Total Debt (Recent Filing)$43.61M
Price to Earnings (P/E)―
Beta2.93
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.97
Shares Outstanding13,019,277
10 Day Avg. Volume722,934
30 Day Avg. Volume515,321
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.13
Price to Sales (P/S)0.19
P/FCF Ratio0.38
Enterprise Value/Market Cap11.85
Enterprise Value/Revenue3.75
Enterprise Value/Gross Profit5.58
Enterprise Value/Ebitda-0.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$2.46M
Bulls Say, Bears Say
Bulls Say
Commercial Product Revenue StreamJaguar’s ownership of Mytesi provides a U.S.-commercialized, FDA-approved product and recurring revenue via specialty/pharmacy channels. FDA approval and payer/reimbursement pathways create a durable revenue base and commercial infrastructure that supports operations and future launches in adjacent indications.
Improved Cash Generation In 2025A reversal to positive operating and free cash flow in 2025 materially strengthens near-term liquidity and reduces immediate financing pressure. If sustained, this improves runway, funds commercialization and development, and lowers reliance on dilutive capital—key for durable operational stability.
Clinical Traction In Rare Intestinal DiseasesClinical acceptance and investigator-led data for crofelemer in rare IF (MVID, SBS) signal proof-of-concept in orphan populations. Orphan indications offer specialty pricing, durable niche demand and lower competition, creating a structurally attractive pathway to diversify revenue beyond the HIV indication.
Bears Say
Negative Equity / Stressed Balance SheetNegative shareholder equity constrains financial flexibility, limits unsecured financing options and increases creditor scrutiny. A stressed capital structure raises the probability of future dilutive financings or onerous borrowing terms, which can durably impair shareholder value and strategic choices.
Persistent Structural Losses & Volatile RevenueJaguar exhibits material revenue volatility and sustained operating losses despite solid gross margins. A cost base not aligned to revenue means profitability depends on consistent top-line growth or structural cost reduction; absent that, loss-making dynamics could persist and limit long-term value creation.
Listing And Capital-structure UncertaintyActive Nasdaq compliance risk, a recent reverse split and broader authorizations to amend share capital signal ongoing listing and dilution risk. Persistent listing uncertainty harms liquidity, investor confidence and access to public capital, constraining durable financing alternatives and strategic execution.
Jaguar Animal Health News
JAGX FAQ
What was Jaguar Animal Health Inc.’s price range in the past 12 months?
Jaguar Animal Health Inc. lowest stock price was $0.24 and its highest was $13.25 in the past 12 months.
What is Jaguar Animal Health Inc.’s market cap?
Jaguar Animal Health Inc.’s market cap is $3.65M.
When is Jaguar Animal Health Inc.’s upcoming earnings report date?
Jaguar Animal Health Inc.’s upcoming earnings report date is May 18, 2026 which is in 18 days.
How were Jaguar Animal Health Inc.’s earnings last quarter?
Jaguar Animal Health Inc. released its earnings results on Apr 07, 2026. The company reported $8.97 earnings per share for the quarter, beating the consensus estimate of N/A by $8.97.
Is Jaguar Animal Health Inc. overvalued?
According to Wall Street analysts Jaguar Animal Health Inc.’s price is currently Overvalued.
Does Jaguar Animal Health Inc. pay dividends?
Jaguar Animal Health Inc. does not currently pay dividends.
What is Jaguar Animal Health Inc.’s EPS estimate?
Jaguar Animal Health Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jaguar Animal Health Inc. have?
Jaguar Animal Health Inc. has 13,019,277 shares outstanding.
What happened to Jaguar Animal Health Inc.’s price movement after its last earnings report?
Jaguar Animal Health Inc. reported an EPS of $8.97 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.244%.
Which hedge fund is a major shareholder of Jaguar Animal Health Inc.?
Currently, no hedge funds are holding shares in JAGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jaguar Animal Health Inc.
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
JAGX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a positive outlook with significant revenue growth and successful clinical trial results for crofelemer, along with strategic regulatory advancements and expansion plans in the animal health market. However, these positive developments were offset by increased operational losses and net loss attributable to shareholders.View all JAGX earnings summariesTechnical Analysis
Galmed Pharmaceuticals
―
Soligenix
―
Revelation Biosciences
―
Dermata Therapeutics
―
60 Degrees Pharmaceuticals, Inc.
―
Ownership Overview
0.80% Insiders
0.47% Mutual Funds
<0.01% Other Institutional Investors
98.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---